Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
948 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02756663 | Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma(PANORAMA-5) | withdrawn | Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Nov 8, 2016 | clinicaltrials |
| NCT01617668 | A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer | completed | Phase 2 | 209 | Novartis PharmaceuticalsINDUSTRY | 12 | Oct 17, 2016 |
| clinicaltrials |
| NCT01035229 | Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.(EVOLVE-1) | completed | Phase 3 | 546 | Novartis PharmaceuticalsINDUSTRY | 18 | Sep 22, 2016 | clinicaltrials |
| NCT00688753 | RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe(MACS0460) | completed | Phase 2 | 92 | Novartis PharmaceuticalsINDUSTRY | 6 | Sep 2, 2016 | clinicaltrials |
| NCT01964235 | Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma | withdrawn | Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 7 | Sep 1, 2016 | clinicaltrials |
| NCT01826214 | Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute Leukemia | completed | Phase 2 | 70 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 30, 2016 | clinicaltrials |
| NCT01132664 | Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer | terminated | Phase 1 / Phase 2 | 72 | Novartis PharmaceuticalsINDUSTRY | 6 | Aug 17, 2016 | clinicaltrials |
| NCT00958841 | Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin | terminated | Phase 2 | 118 | Novartis PharmaceuticalsINDUSTRY | 12 | Jul 26, 2016 | clinicaltrials |
| NCT01528345 | Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer | terminated | Phase 2 | 97 | Novartis PharmaceuticalsINDUSTRY | 15 | Jul 11, 2016 | clinicaltrials |
| NCT01034163 | A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL)(PATH) | completed | Phase 3 | 41 | Novartis PharmaceuticalsINDUSTRY | 14 | Jul 7, 2016 | clinicaltrials |
| NCT00785785 | A Study of Nilotinib Versus Imatinib in GIST Patients(ENESTg1) | completed | Phase 3 | 644 | Novartis PharmaceuticalsINDUSTRY | 35 | Jun 16, 2016 | clinicaltrials |
| NCT01491672 | Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma(RECORD-4) | completed | Phase 2 | 134 | Novartis PharmaceuticalsINDUSTRY | 6 | Jun 6, 2016 | clinicaltrials |
| NCT01350804 | Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)(NURTURE 1) | completed | Phase 3 | 551 | Novartis PharmaceuticalsINDUSTRY | 15 | May 23, 2016 | clinicaltrials |
| NCT01365468 | Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1) | terminated | Phase 2 | 9 | Novartis PharmaceuticalsINDUSTRY | 1 | May 12, 2016 | clinicaltrials |
| NCT00567879 | A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After Trastuzumab | terminated | Phase 1 / Phase 2 | 56 | Novartis PharmaceuticalsINDUSTRY | 6 | May 9, 2016 | clinicaltrials |
| NCT01658436 | BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy. | completed | Phase 2 | 31 | Novartis PharmaceuticalsINDUSTRY | 9 | May 2, 2016 | clinicaltrials |
| NCT02002689 | LDE225 for Patients With PTCH1 or SMO Mutated Tumors(SIGNATURE) | terminated | Phase 2 | 10 | Novartis PharmaceuticalsINDUSTRY | 1 | May 2, 2016 | clinicaltrials |
| NCT01478373 | Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib | completed | Phase 2 | 39 | Novartis PharmaceuticalsINDUSTRY | 5 | Apr 27, 2016 | clinicaltrials |
| NCT00428909 | Effect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP) | completed | Phase 1 | 12 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 21, 2016 | clinicaltrials |
| NCT02143622 | Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell Carcinoma Patients | withdrawn | Phase 1 / Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Apr 21, 2016 | clinicaltrials |
| NCT00248170 | Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer(FACE) | completed | Phase 3 | 4,172 | Novartis PharmaceuticalsINDUSTRY | 20 | Apr 19, 2016 | clinicaltrials |
| NCT00241020 | Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 3 | 270 | Novartis PharmaceuticalsINDUSTRY | 0 | Apr 12, 2016 | clinicaltrials |
| NCT01043874 | Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response(MACS0911) | completed | Phase 4 | 45 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 8, 2016 | clinicaltrials |
| NCT01275196 | Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients | completed | Phase 3 | 267 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 8, 2016 | clinicaltrials |
| NCT01628913 | Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors | terminated | Phase 2 | 62 | Novartis PharmaceuticalsINDUSTRY | 8 | Apr 7, 2016 | clinicaltrials |
| NCT00422825 | Effect of Food on Bioavailability of a Modified Release Formulation of Imatinib | completed | Phase 1 | 16 | Novartis PharmaceuticalsINDUSTRY | 0 | Apr 5, 2016 | clinicaltrials |
| NCT02221505 | Phase 1 Study of LOP628 in Adult Patients With cKit-positive Solid Tumors and Acute Myeloid Leukemia | terminated | Phase 1 | 3 | Novartis PharmaceuticalsINDUSTRY | 4 | Apr 5, 2016 | clinicaltrials |
| NCT01317615 | RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation | completed | Phase 4 | 49 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 30, 2016 | clinicaltrials |
| NCT01297491 | Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer(BASALT-1) | completed | Phase 2 | 63 | Novartis PharmaceuticalsINDUSTRY | 18 | Mar 11, 2016 | clinicaltrials |
| NCT01151410 | An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age | completed | Phase 3 | 208 | Novartis PharmaceuticalsINDUSTRY | 7 | Mar 7, 2016 | clinicaltrials |
| NCT01254188 | Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients(ENESTxtnd) | completed | Phase 3 | 421 | Novartis PharmaceuticalsINDUSTRY | 19 | Mar 3, 2016 | clinicaltrials |
| NCT01124864 | A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy. | completed | Phase 2 | 153 | Novartis PharmaceuticalsINDUSTRY | 10 | Mar 2, 2016 | clinicaltrials |
| NCT01433263 | Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas | completed | Phase 2 | 57 | Novartis PharmaceuticalsINDUSTRY | 5 | Mar 2, 2016 | clinicaltrials |
| NCT01227577 | CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib(MACS1428) | completed | Phase 4 | 128 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 8, 2016 | clinicaltrials |
| NCT00789828 | Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1)(EXIST-1) | completed | Phase 3 | 117 | Novartis PharmaceuticalsINDUSTRY | 10 | Feb 3, 2016 | clinicaltrials |
| NCT01390519 | A Norwegian Observational Trial Evaluating the Treatment of Advanced Renal Cell Cancer Patients Under Treatment of Afinitor(OSAT) | completed | — | 30 | Novartis PharmaceuticalsINDUSTRY | 1 | Jan 13, 2016 | clinicaltrials |
| NCT02204553 | Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 1 | Jan 5, 2016 | clinicaltrials |
| NCT01919229 | A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)(MONALEESA-1) | terminated | Phase 2 | 14 | Novartis PharmaceuticalsINDUSTRY | 3 | Jan 1, 2016 | clinicaltrials |
| NCT01028222 | A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation(TEAM) | completed | Phase 2 | 55 | Novartis PharmaceuticalsINDUSTRY | 14 | Dec 30, 2015 | clinicaltrials |
| NCT00426556 | Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer | completed | Phase 1 | 88 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 28, 2015 | clinicaltrials |
| NCT00866281 | A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia | terminated | Phase 1 / Phase 2 | 22 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 22, 2015 | clinicaltrials |
| NCT01223027 | Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma | completed | Phase 3 | 564 | Novartis PharmaceuticalsINDUSTRY | 27 | Dec 7, 2015 | clinicaltrials |
| NCT01232296 | A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment | completed | Phase 2 | 162 | Novartis PharmaceuticalsINDUSTRY | 7 | Dec 4, 2015 | clinicaltrials |
| NCT00802841 | Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib(LASOR) | completed | Phase 3 | 191 | Novartis PharmaceuticalsINDUSTRY | 12 | Nov 16, 2015 | clinicaltrials |
| NCT00116376 | Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM) | completed | Phase 1 / Phase 2 | 64 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 10, 2015 | clinicaltrials |
| NCT00879333 | Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)(GRANITE-1) | completed | Phase 3 | 656 | Novartis PharmaceuticalsINDUSTRY | 22 | Nov 3, 2015 | clinicaltrials |
| NCT00961896 | A Trial to Evaluate the Safety, Local Tolerability, Pharmacokinetics and Pharmacodynamics of LDE225 on Skin Basal Cell Carcinomas in Gorlin Syndrome Patients | completed | Phase 2 | 18 | Novartis PharmaceuticalsINDUSTRY | 2 | Nov 3, 2015 | clinicaltrials |
| NCT01033019 | To Evaluate the Safety, Local Tolerability, PK and PD of LDE225 on Sporadic Superficial and Nodular Skin Basal Cell Carcinomas (sBCC) | terminated | Phase 2 | 25 | Novartis PharmaceuticalsINDUSTRY | 2 | Oct 30, 2015 | clinicaltrials |
| NCT01350115 | Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS) | completed | Phase 2 | 10 | Novartis PharmaceuticalsINDUSTRY | 4 | Oct 19, 2015 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials